Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

Sep 13, 2018

• Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a

• MS severely affects the everyday lives of children and adolescents with the disease and carries a significant impact throughout their lifetime

• Gilenya, a leading oral therapy for relapsing MS, is the only treatment approved by the US FDA for patients from 10 years of age through to adulthood 

CONTINUE reading the complete detail 

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

To receive MS news and information via e-mail, Please Click here 

                     

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::